Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

AbCellera Biologics Temettü

Temettü kriter kontrolleri 0/6

AbCellera Biologics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	0.3%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$0.52
Temettü verim tahmini	0%

Son temettü güncellemeleri

Güncelleme yok

Recent updates

AbCellera: A Waiting Game With High Uncertainty

Aug 23

Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth

May 29

AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate

Nov 29

AbCellera Biologics: Many Reasons To Own This Undervalued Stock

Sep 06

AbCellera Biologics: COVID Antibody Set To Provide Continued Funding

Aug 14

AbCellera partnering with Atlas Ventures on development of therapeutic antibodies

Aug 03

AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying

Jun 06

Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)

May 13

Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%

May 07

AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment

Apr 22

AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm

Feb 11

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: ABCL şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: ABCL şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

AbCellera Biologics Piyasaya Karşı Temettü Getirisi

ABCL temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (ABCL)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.3%
Sektör Ortalaması (Life Sciences)	0.3%
Analist tahmini (ABCL) (3 yıla kadar)	0%

Önemli Temettü: ABCL şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, ABCL şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: ABCL şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: ABCL herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

AbCellera Biologics Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

AbCellera Biologics Inc. to Report Q3, 2024 Results on Nov 04, 2024

CEO, President & Chairperson exercised options to buy US$137k worth of stock.

CEO, President & Chairperson recently bought US$740k worth of stock

AbCellera: A Waiting Game With High Uncertainty

Consensus revenue estimates decrease by 20%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

AbCellera Biologics Inc. to Report Q2, 2024 Results on Aug 06, 2024

CEO, President & Chairperson exercised options to buy US$212k worth of stock.

Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth

AbCellera: Cash Providing Shelter From Market Weakness

Consensus revenue estimates decrease by 16%, EPS upgraded

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

AbCellera Biologics Inc., Annual General Meeting, Jun 13, 2024

AbCellera Biologics Inc. to Report Q1, 2024 Results on May 07, 2024

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

Consensus revenue estimates fall by 20%

AbCellera: Victim Of Its Own Success

AbCellera Biologics Inc. Announces Board Changes

AbCellera Biologics: Continuing To Expand Partnerships

AbCellera Biologics Inc. to Report Fiscal Year 2023 Results on Feb 20, 2024

Abcellera Biologics, Inc. Announces Reorganization

Consensus revenue estimates decrease by 16%, EPS upgraded

AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

AbCellera Biologics Inc. to Report Q3, 2023 Results on Nov 02, 2023

Price target decreased by 8.0% to US$24.38

Consensus EPS estimates upgraded to US$0.46 loss, revenue downgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights' Request for Rehearing

AbCellera Biologics Inc. to Report Q2, 2023 Results on Aug 03, 2023

DAMONA Pharmaceuticals Appoints John Reilly as Member of the Board of Directors

CEO, President & Chairperson exercised options to buy US$391k worth of stock.

Chief Financial Officer recently bought US$99k worth of stock

First quarter 2023 earnings: EPS misses analyst expectations

CEO, President & Chairperson exercised options to buy US$470k worth of stock.

Full year 2022 earnings: EPS and revenues miss analyst expectations

Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?

AbCellera Biologics Inc. to Report Fiscal Year 2022 Results on Feb 21, 2023

CEO, President & Chairperson recently bought US$859k worth of stock

Investor sentiment deteriorated over the past week

AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate

CEO, President & Chairperson exercised options to buy US$786k worth of stock.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improved over the past week

AbCellera Biologics Inc. to Report Q3, 2022 Results on Nov 08, 2022

Investor sentiment improved over the past week

AbCellera Biologics: Many Reasons To Own This Undervalued Stock

CEO, President & Chairperson recently bought US$2.3m worth of stock

Investor sentiment deteriorated over the past week

AbCellera Biologics: COVID Antibody Set To Provide Continued Funding

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

AbCellera partnering with Atlas Ventures on development of therapeutic antibodies

AbCellera Biologics Inc. to Report Q2, 2022 Results on Aug 09, 2022

AbCellera Biologics Inc. Announces Departure of Neil Berkley as Chief Business Officer

CEO, President & Chairperson recently bought US$515k worth of stock

CEO, President & Chairperson recently bought US$484k worth of stock

AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying

CEO, President & Chairperson exercised options to buy US$443k worth of stock.

CEO, President & Chairperson recently bought US$9.0m worth of stock

Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%

Consensus EPS estimates increase by 21%

Price target decreased to US$33.38

AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment

AbCellera Biologics Inc. to Report Q1, 2022 Results on May 10, 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Independent Non-Employee Director recently bought US$181k worth of stock

Consensus revenue estimates increase by 66%

CEO, President & Chairperson exercised options to buy US$501k worth of stock.

Investor sentiment deteriorated over the past week